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Table 1
pharmacokinetic data of intravenous busulfan
No TDM
n [ 50
TDM
n [ 50
cAUC, mean (range) in mg*h/L 85.3 (45 e 156) 96.2 (74 e 117)
Patients within target cAUC
80 - 100 mg*h/L, n (%)
17 (34%) 35 (70%)
A total exposure of 90 mg*h/L relates to 21.6 mM*min total, or 5400
mM*min/day
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transplant, at the Catholic University Health Network, Chile,
followed 1 year after transplantation.
Results: We analyzed 97 patients, average 37 years old
(range: 15-68 years). Main indications for HSCT were he-
matologic malignancies (84%, n¼82), mainly acute lympho-
blastic leukemia (29%, n¼28), acute myeloid leukemia (21%,
n¼20), non-Hodgkin lymphoma (13%, n¼13) and multiple
myeloma (13%, n¼13). Ninety percent of the patients (n¼87)
received myeloablative conditioning regimens including
drugs like cyclophosphamide, carmustine, melphalan, eto-
poside, busulfan and total body irradiation. Twenty nine
percent of the patients (n¼28/97) were admitted in the ICU
(autologous HSCT: 15% [n: 5/33]; allogeneic HSCT: 32%
[n¼13/41]; cord blood HSCT: 43% [n¼10/23]) with an average
stay of 19 days (range: 1-73 days) (autologous: 13 days,
allogeneic: 16 days, cord blood: 22 days). The median time
from admission to transplant to ICU transfer occurred at day
15 after transplantation (autologous: day 3, allogeneic: day
16, cord blood: day 22). Main causes for admission were
acute respiratory failure (63%), septic shock (19%) and
neurological complications (19%), with similar distribution
between the different types of transplants. Among the pa-
tients admitted to ICU, 20% (n¼1/5) of autologous, 69% (n¼9/
13) of allogeneic and 70% (n¼7/10) of the cord blood HSCT
died in the unit. Patients died in the ICU 108 days average
after transplantation (range: 4-320) (autologous: 10 days,
allogeneic: 131 days, cord blood: 119 days). One-year OS of
patients who survived the ICU vs patients never admitted to
the ICU was 53% and 85%, respectively (p¼0.0036). For
allogeneic HSCT, 1-year OS was 15% vs 85% (p<0.0001), for
cord blood transplantation 1-year OS was 20% vs 84%
(P¼0.0008) and for autologous HSCT 1-year OS was 80% vs
89% (pNS), after comparing patients who survived the ICU vs
patients never admitted to the ICU, respectively.
Conclusions: Although mortality of HSCT recipients
admitted in ICU is high, our results show that intensive
support can be beneﬁcial in about half of patients who were
admitted, with short to medium outcomes not so unfavor-
able than has been previously reported.Figure 1. busulfan exposure for each patient384
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Busulfan (Bu) is an alkylating drug used in conditioning
regimens for hematopoietic cell transplantation (HCT).
Optimal myelo-ablative exposure of Bu is assumed to be 90
mg*h/L when given in combination with ﬂudarabine leading
to optimal (event free) survival rates. Despite the availability
of intravenous Bu instead of the oral formulation, there is still
wide inter-individual variability in Bu pharmacokineticsafter intravenous administration, particularly in children. An
individual dosing nomogram based on a pharmacokinetic
(PK) model has been developed by Bartelink et al (Clin
Pharmacokinet 2012) that is expected to result in more
predictive Bu exposure and thereby to a safer and more
effective conditioning regimen. The aims of this study are to
(i) prospectively investigate target attainment of the dosing
nomogram and (ii) assess the additive value of therapeutic
drug monitoring (TDM).
Methods: Bu was administered once daily in a 3-hour infu-
sion on 4 consecutive days. Drug levels were measured on
day 1 and 4 and Bu exposure was calculated as cumulative
area under the concentration-time curve day 1-4 (cAUC)
using MWPharm 3.60. The accuracy and precision of the
dosing nomogram was assessed by comparing cAUC based
only on model prediction (90 mg*h/L) with the observed
cAUC for each individual patient based on PK data on day 1
(No TDM). Without TDM cAUC was calculated based on PK
data on day 1 extrapolated to day 1-4. With TDM cAUC was
determined on PK data on day 1 and 4, including dose
adjustment. To assess the additive value of TDM the per-
centage patients within target cAUC 80 e 100 mg*h/L were
compared for the situation that no TDMwould be performed
and the situation with TDM.
Results: 50 consecutive pediatric HCT patients (age 3
monthse 18 year) were included between 2011 and 2012. Bu
exposure for each patient is shown in ﬁgure 1. Without TDM
mean cAUC is 85,3 mg*h/L, this corresponds well with the
predicted cAUC of 90 mg*h/L based on the PK model. The
range of cAUC for individual patients however is very large
(table 1). Without TDM only 34% of patients reached target
cAUC and with TDM this was 70% of patients.
Conclusions: This prospective validation shows that the
bodyweight based dosing nomogram overall leads to a mean
Bu exposure of 90 mg*h/L in patients between 3 months and
18 years. Some remaining unexplained variability between
patients and between days, however, still leads to variability
in exposure. Therefore TDM of intravenous Bu is still needed
and of utmost importance to reach optimal target exposure
in pediatric patients in order to optimize outcomes of HCT.
